Mechanisms of venetoclax resistance and solutions: The BCL-2 inhibitor venetoclax is currently approved for treatment of hematologic diseases and is widely used either as monotherapy or in combination strategies. It has produced… #oncology https://t.co/jf8
RT @FrontOncology: New research: Mechanisms of venetoclax resistance and solutions: The BCL-2 inhibitor venetoclax is currently approved fo…
RT @FrontOncology: New research: Mechanisms of venetoclax resistance and solutions: The BCL-2 inhibitor venetoclax is currently approved fo…
New research: Mechanisms of venetoclax resistance and solutions: The BCL-2 inhibitor venetoclax is currently approved for treatment of hematologic diseases and is widely used either as monotherapy or in combination strategies. It has produced… https://t.co